|  |  |  | **Trimester** | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **T1** | | **T2** | | **T3** | |
|  |  |  | **Exposed** | | | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 2,194 | 2,195 | 3,485 | 3,456 | 2,819 | 2,847 |
| Age | - | Median [Q25 - Q75] | 32.00 [28.00 - 36.00] | 32.00 [27.00 - 36.00] | 33.00 [29.00 - 36.00] | 33.00 [29.00 - 36.00] | 33.00 [28.00 - 36.00] | 33.00 [29.00 - 36.00] |
| Age group | 12 to 24 | N (%) | 290 (13.2%) | 288 (13.1%) | 327 (9.4%) | 337 (9.8%) | 282 (10.0%) | 267 (9.4%) |
|  | 25 to 39 | N (%) | 1,749 (79.7%) | 1,749 (79.7%) | 2,830 (81.2%) | 2,797 (80.9%) | 2,266 (80.4%) | 2,314 (81.3%) |
|  | 40 to 55 | N (%) | 155 (7.1%) | 158 (7.2%) | 328 (9.4%) | 322 (9.3%) | 271 (9.6%) | 266 (9.3%) |
| Vaccine brand | Moderna | N (%) | 513 (23.4%) | 513 (23.4%) | 657 (18.9%) | 640 (18.5%) | 509 (18.1%) | 526 (18.5%) |
|  | Pfizer | N (%) | 1,681 (76.6%) | 1,682 (76.6%) | 2,828 (81.1%) | 2,816 (81.5%) | 2,310 (81.9%) | 2,321 (81.5%) |
| Trimester | Trimester 1 | N (%) | 2,194 (100.0%) | 2,195 (100.0%) | - | - | - | - |
|  | Trimester 2 | N (%) | - | - | 3,485 (100.0%) | 3,456 (100.0%) | - | - |
|  | Trimester 3 | N (%) | - | - | - | - | 2,819 (100.0%) | 2,847 (100.0%) |
| Number visits prior year | - | Median [Q25 - Q75] | 11.00 [4.00 - 21.00] | 20.00 [8.00 - 38.00] | 16.00 [9.00 - 29.00] | 32.00 [18.00 - 52.00] | 22.00 [13.00 - 35.00] | 42.00 [26.00 - 64.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 569 (25.9%) | 484 (22.1%) | 809 (23.2%) | 744 (21.5%) | 776 (27.5%) | 678 (23.8%) |
|  | Heart conditions | N (%) | 46 (2.1%) | 48 (2.2%) | 70 (2.0%) | 94 (2.7%) | 54 (1.9%) | 64 (2.2%) |
|  | Eclampsia preeclampsia | N (%) | 17 (0.8%) | 21 (1.0%) | 42 (1.2%) | 34 (1.0%) | 26 (0.9%) | 39 (1.4%) |
|  | Asthma | N (%) | 107 (4.9%) | 110 (5.0%) | 198 (5.7%) | 232 (6.7%) | 139 (4.9%) | 185 (6.5%) |
|  | Pneumonia | N (%) | 59 (2.7%) | 78 (3.6%) | 90 (2.6%) | 123 (3.6%) | 95 (3.4%) | 83 (2.9%) |
|  | Hypothyroidism | N (%) | 172 (7.8%) | 169 (7.7%) | 270 (7.7%) | 302 (8.7%) | 234 (8.3%) | 282 (9.9%) |
|  | Depressive disorder | N (%) | 114 (5.2%) | 129 (5.9%) | 192 (5.5%) | 201 (5.8%) | 163 (5.8%) | 161 (5.7%) |
|  | Gestational diabetes | N (%) | 77 (3.5%) | 77 (3.5%) | 188 (5.4%) | 169 (4.9%) | 234 (8.3%) | 253 (8.9%) |
|  | Chronic hypertension | N (%) | 39 (1.8%) | 43 (2.0%) | 76 (2.2%) | 87 (2.5%) | 56 (2.0%) | 72 (2.5%) |
|  | Anxiety disorder | N (%) | 598 (27.3%) | 597 (27.2%) | 976 (28.0%) | 962 (27.8%) | 784 (27.8%) | 782 (27.5%) |
|  | Chronic obstructive lung disease | N (%) | 0 (0.0%) | <5 (<5%) | <5 (<5%) | 6 (0.2%) | <5 (<5%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 89 (4.1%) | 98 (4.5%) | 149 (4.3%) | 137 (4.0%) | 93 (3.3%) | 99 (3.5%) |
|  | Progestogens | N (%) | 125 (5.7%) | 83 (3.8%) | 194 (5.6%) | 254 (7.3%) | 134 (4.8%) | 121 (4.3%) |
|  | Antimycotics systemic | N (%) | 9 (0.4%) | 14 (0.6%) | 22 (0.6%) | 21 (0.6%) | 7 (0.2%) | 11 (0.4%) |
|  | Estrogens | N (%) | 209 (9.5%) | 201 (9.2%) | 251 (7.2%) | 253 (7.3%) | 149 (5.3%) | 150 (5.3%) |
|  | Antithrombotics | N (%) | 61 (2.8%) | 42 (1.9%) | 159 (4.6%) | 144 (4.2%) | 225 (8.0%) | 194 (6.8%) |
|  | Antihistamines systemic | N (%) | 252 (11.5%) | 261 (11.9%) | 559 (16.0%) | 619 (17.9%) | 422 (15.0%) | 462 (16.2%) |
|  | Antidepressants | N (%) | 104 (4.7%) | 150 (6.8%) | 169 (4.8%) | 167 (4.8%) | 130 (4.6%) | 140 (4.9%) |
|  | Immunoglobulins | N (%) | 5 (0.2%) | 9 (0.4%) | 67 (1.9%) | 68 (2.0%) | 290 (10.3%) | 256 (9.0%) |
|  | Analgesics and antipyretics | N (%) | 600 (27.3%) | 617 (28.1%) | 1,228 (35.2%) | 1,232 (35.6%) | 1,025 (36.4%) | 1,061 (37.3%) |
|  | Antiinflammatory antirehumatic | N (%) | 551 (25.1%) | 562 (25.6%) | 556 (16.0%) | 523 (15.1%) | 198 (7.0%) | 202 (7.1%) |
|  | Antiepileptics | N (%) | 27 (1.2%) | 56 (2.6%) | 57 (1.6%) | 56 (1.6%) | 27 (1.0%) | 30 (1.1%) |
|  | Antibacterials systemic | N (%) | 427 (19.5%) | 459 (20.9%) | 857 (24.6%) | 856 (24.8%) | 675 (23.9%) | 671 (23.6%) |